Nanotechnology Now - Press Release: Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013

Home > Press > Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013

Abstract:
50th Conference Will Feature Premier Investors Such as Biomet, BioVentures Investors, Claremont Creek Ventures, Fletcher Spaght Ventures, Hercules Technology Growth Capital, Hologic, H.I.G. BioVentures, Johnson & Johnson, Lumira Capital, Mass Medical Angels, Pappas Ventures, Philips Healthcare, Psilos Group, SV Life Sciences, Third Rock Ventures, Triathlon Medical Ventures, and Western Technology Investment

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013

Boston, MA | Posted on May 20th, 2013

Elsevier Business Intelligence, the medtech industry's leading provider of strategic partnership and investment conferences, announced today that it will host the 'IN3 Medical Device 360° Boston' investor conference on June 24-26, 2013, at the Hyatt Regency Boston. There are many emerging companies that are presenting at an IN3 event for the first time, including Actium Biosystems and Cognoptix.

Actium (Boulder, Colo.) has developed a magnetic energy-illuminated nanotechnology platform that selectively heats targeted tissue to enhance the efficacy of traditional chemo and radiation therapies. The first application of the Actium Cancer Treatment (ACT) platform is in support of intravesical chemotherapy in the treatment of non-muscle invasive bladder cancer (NMIBC). CEO Joe Tondu will be introducing the ACT platform technology for the first time to the healthcare community at IN3 in Boston. "We expect the IN3 event to be a great place to network, where we'll have the chance to meet not only senior-level decision-makers from the investment community but also from major medtech and pharma companies," said Tondu.

Cognoptix (Acton, Mass.) has developed an entirely novel, early-stage diagnostic eye test for Alzheimer's disease (AD) to allow treatment before significant neuronal loss and irreversible brain damage occurs. CEO Paul Hartung, who orchestrated the first-ever Series A syndicated angel deal in the Northeast, will present the Cognoptix opportunity. "The medtech industry needs great events like IN3 where there's a critical mass of emerging companies intersecting with serious investors," added Hartung.

The Investment in Innovation (IN3) Medical Device 360° Boston conference will feature presentations by more than 30 early-, mid- and late-stage start-up companies that are seeking funding and/or strategic partnership across the spectrum of diagnostic and therapeutic device markets. The conference also will feature an outstanding agenda of panels, networking sessions and meet-and-greets with industry thought leaders discussing the most pressing issues facing the global device industry in 2013 and beyond. Panel topics will include: What Acquirers Want to See in a Start-Up Before Buying; Alternative Financing Strategies for Capital: When and Where to Find Them; and, Medtech Investing: Hear What It Takes to Get a VC to Say 'Yes!' In addition, large company/VC meet-and-greets will be held to facilitate interaction between these two influential groups and conference participants. Partnering software will be available to all registered attendees prior to the conference so that one-on-one onsite meetings can be pre-arranged.

In addition to all of the customary conference benefits, presenting company CEOs will have the opportunity to be interviewed on camera, at no charge, for a 3-minute exclusive video in which they may discuss their company and technology. These interviews will be featured post-conference at www.in3tv.com, to which a link will be provided to participating companies for their unrestricted use; availability of these video interviews will be broadly promulgated within the medtech industry. All one-on-one interviews with presenting-company CEOs will take place at, and during the IN3 Boston conference and be organized by medtech PR/IR expert Ronald Trahan, President of Ronald Trahan Associates, Inc. Videotaping will take place on a scheduled basis only, on one day only of the event: Tuesday, June 25, from 1:00-5:30 p.m. EDT. To schedule the free on-camera interviews contact or call +1-508-359-4005, x108.

This special event will benefit a wide variety of participants in the medical device sector: start-ups seeking investment or strategic partnerships, investment firms, VCs, mid-size and large medical device manufacturers, and service providers. Emerging medtech companies that would like to apply to present in Boston should contact Kayleen Kell at 949-797-7142, or email

IN3 Medical Device 360° Boston will be held at the Hyatt Regency Boston. Event co-sponsors to date include Ronald Trahan Associates Inc., Marketwired, MassMEDIC, Mass Medical Angels, Massachusetts Life Sciences Center, MedMarc, CanBiotech™ Innovations, Emerson Consultants, Enterprise Ireland, Venture Valuation, Pharma Connections Worldwide, AppFolio Secure Docs, and Life Science Intelligence. Visit www.in3Boston.com for more information.

####

About Elsevier Business Intelligence
Elsevier Business Intelligence (EBI), an Elsevier company built on the heritage of F-D-C Reports, Windhover Information and Medtech Insight, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

For more information, please click here

Contacts:
Ronald Trahan, APR
Ronald Trahan Associates Inc.
508-359-4005, x108

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: